Avapritinib (Ayvakit) for GIST
Date: February 8, 2021
Issue #:
1617Summary:
The FDA has approved the oral tyrosine kinase
inhibitor avapritinib (Ayvakit– Blueprint Medicines)
for treatment of unresectable or metastatic gastrointestinal
stromal tumors (GISTs) harboring a
platelet-derived growth factor receptor alpha
(PDGFRA) D842V or other PDGFRA exon 18 mutation.
Avapritinib is the first drug to be approved for this
indication in the US.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: admin Tags: avapritinib Ayvakit GIST Gleevec Imatinib regorafenib Stivarga sunitinib Sutent Source Type: research